Peptides

Sarafotoxin S6b, sourced from the venom of the Atractaspis engaddensis snake family, is one of four (S6a-d) isopeptides of the Sarafotoxins. This product is a synthetically produced toxin, containing disulfide bonds between Cys1-Cys15 and Cys3-Cys11.Due to their structural and functional homology to the endothelin peptides, Sarafotoxins can enhance vasoconstriction through stimulating the class A G-protein-coupled, endothelin ETA and ETB receptors. This in turn leads to left ventricular dysfunction and bronchoconstriction.
As the most potent Sarafotoxin, sarafotoxin S6b binds to both ETA and ETB receptors with a similar affinity to Endothelin-1. This is evident as when given to mice intravenously, sarafotoxin S6b caused cardiac arrest and death in mice almost immediately. Additional characteristics of S6b is its matrix metalloproteinase inhibitory activity due to it exhibiting a fold which is also found in the core region of tissue inhibitors of metalloproteinases (TIMPs).
Sarafotoxin S6b can be used as a pharmacological reagent to study the interactions of Endothelins and their corresponding receptors. This product is available as a 0.1mg vial.

Glucagon (Human) is a recombinant peptide hormone, which is synthesized to mimic the natural glucagon produced by alpha cells in the pancreas. This biopharmaceutical is derived from a DNA recombinant technology source, offering a high level of purity and consistency. Its mode of action involves binding to glucagon receptors on liver cells, stimulating glycogenolysis and gluconeogenesis. This results in the rapid conversion of glycogen into glucose, thereby raising blood sugar levels.Glucagon (Human) is primarily utilized in the treatment of severe hypoglycemia, especially in diabetic patients unable to consume oral glucose due to unconsciousness or confusion. Its application is critical in acute settings where rapid intervention is necessary to prevent neurological damage from prolonged hypoglycemia. Additionally, the research and clinical use of glucagon extend to investigating its potential in counteracting beta-blocker and calcium channel blocker overdoses, where it acts to increase cardiac output. This hormone's pharmaceutical development has provided a crucial tool in both emergency response and broader therapeutic research contexts.

A synthetic peptide for use as a blocking control in assays to test for specificity of SETD2 antibody, catalog no. 20R-1264

A synthetic peptide for use as a blocking control in assays to test for specificity of DUS1L antibody, catalog no. 70R-4013

A synthetic peptide for use as a blocking control in assays to test for specificity of TOLLIP antibody, catalog no. 70R-5778

A synthetic peptide for use as a blocking control in assays to test for specificity of NEK11 antibody, catalog no. 70R-2292

A synthetic peptide for use as a blocking control in assays to test for specificity of KIF21A antibody, catalog no. 70R-5567

A synthetic peptide for use as a blocking control in assays to test for specificity of COMMD1 antibody, catalog no. 70R-10355

A synthetic peptide for use as a blocking control in assays to test for specificity of PES1 antibody, catalog no. 70R-3107

A synthetic scorpion toxin consisting of disulfide bonds between Cys3-Cys17, Cys10-Cys21, and Cys16-Cys32. It can be used as an activator of Ca2+ Release Channels/Ryanodine Receptors. It is important to understand the functions of Ryanodine receptors as they mediate Ca2+ release from intracellular reticular stores and this is imperative for signalling processes, namely muscle excitation-contraction coupling. If skeletal and cardiac Ryanodine receptor genes are mutated diseases such as congenital myopathy and metabolic disorders occur. Therefore Imperatoxin A is useful in investigating these diseases. This product is avaiable as a 0.1mg vial.

A synthetic peptide for use as a blocking control in assays to test for specificity of SNRPA antibody, catalog no. 70R-4992

A synthetic peptide for use as a blocking control in assays to test for specificity of FAM118A antibody, catalog no. 70R-4554

A synthetic peptide for use as a blocking control in assays to test for specificity of CYP3A4 antibody, catalog no. 70R-7491

A synthetic peptide for use as a blocking control in assays to test for specificity of RAD51L1 antibody, catalog no. 70R-9528

A synthetic peptide for use as a blocking control in assays to test for specificity of CSNK2A2 antibody, catalog no. 70R-3332

A synthetic peptide for use as a blocking control in assays to test for specificity of MAT2B antibody, catalog no. 70R-3455

A synthetic peptide for use as a blocking control in assays to test for specificity of GALE antibody, catalog no. 70R-9266

A synthetic peptide for use as a blocking control in assays to test for specificity of GPI antibody, catalog no. 70R-10234

A synthetic peptide for use as a blocking control in assays to test for specificity of DNAJC10 antibody, catalog no. 70R-6576

A synthetic peptide for use as a blocking control in assays to test for specificity of ECHDC2 antibody, catalog no. 70R-5270